Trial reportAddiction biology2013
Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
Trial report in Addiction biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review.Current atherosclerosis reports · 2017Pooled it
- The effect of a synthetic cannabinoid agonist (nabilone) on unimodal tactile illusion correlates with a psychometric scores in healthy volunteers.Scientific reports · 2025Trial
- Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.The Journal of pharmacology and experimental therapeutics · 2024Trial
- The effects of caffeine and d-amphetamine on spatial span task in healthy participants.PloS one · 2023Trial
- The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Trial
- Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.Drug and alcohol dependence · 2017Trial
- Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.Psychopharmacology · 2016Trial
- Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.Drug and alcohol dependence · 2016Trial
- Safety of oral dronabinol during opioid withdrawal in humans.Drug and alcohol dependence · 2015Trial
- The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.Drug and alcohol dependence · 2015Trial
- Marijuana's dose-dependent effects in daily marijuana smokers.Experimental and clinical psychopharmacology · 2013Trial
- Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.The journal of headache and pain · 2012Trial
- Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder.Journal of clinical psychopharmacologyTrial
- Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement.AAPS PharmSciTech · 2026Review
- Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Predicting Δ-9-Tetrahydrocannabinol-Induced Psychoactive and Cognitive Effects: A PBPK-PD Approach to Quantifying Feeling High and Reduced Alertness.ACS chemical neuroscience · 2025Article
- The relationship between cannabis and cardiovascular disease: clearing the haze.Nature reviews. Cardiology · 2025Review
- Arrhythmias and cannabis use: A comprehensive overview.Heart rhythm O2 · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.